PARP inhibitors

[Pharmacogenomics] Scientists summarize the key poly-(ADP-ribose) polymerase inhibitors, which act in cells with defects in homologous recombination DNA repair caused by genomic aberrations such as BRCA mutations, that are published and ongoing trials in prostate cancer.

[Journal of Translational Medicine] Programmed death ligand 1 (PD-L1) expression in human ovarian cancer cells after PARP inhibitors treatment was examined by western blotting and flow cytometry.

[Blood Advances] Investigators demonstrated the relevance of genetic germline diagnostics in elucidating the causes of myeloproliferative neoplasms (MPNs) and suggested novel therapeutic options in MPNs.

[npj Breast Cancer] In cell lines, BRCA1 loss was associated with stabilized cyclin E1 during the cell cycle, and BRCA1 siRNA led to increased cyclin E1 in association with reduced phospho-cyclin E1 T62.

[Nature Reviews Clinical Oncology] Scientists summarize the diverse processes underlying resistance to poly(ADP-ribose) polymerase (PARP) inhibitors and discuss the potential strategies that might overcome these mechanisms such as combinations with chemotherapies, targeting the acquired vulnerabilities associated with resistance to PARP inhibitors or suppressing genomic instability.

[Cell Reports] Genetic deletion or methylation of DNA-sensing/IFN genes or CCL5 chemokine was identified as a potential mechanism to attenuate T cell inflammation.